Lisa M Ingerski1, Robert N Baldassano, Lee A Denson, Kevin A Hommel. 1. Center for the Promotion of Treatment Adherence and Self-Management, Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave., MLC 7039, Cincinnati, OH 45229-3039, USA.
Abstract
OBJECTIVE: To identify family-reported, adherence-related barriers for adolescents with inflammatory bowel disease (IBD) and examine their relationship to 6-MP/azathioprine and 5-ASA medication adherence. METHODS: Participants included 74 adolescents, aged 13-17 years, diagnosed with IBD and their caregivers. Adolescents and caregivers jointly completed a measure of barriers to medication adherence. Adherence to medication was measured by family-report, pill-count, and serum assay. RESULTS: Families endorsed one to seven total barriers to medication adherence. The most commonly reported barriers included forgetting, being away from home, and interference with an activity. Neither demographic nor disease severity variables were related to the total number of reported barriers. Fewer total reported barriers was related to better adherence by adolescent and maternal report. CONCLUSION: Most families experience at least one barrier to treatment adherence. Effective problem-solving around these barriers and its integration into future treatment protocols may help improve medication adherence in the pediatric IBD population.
OBJECTIVE: To identify family-reported, adherence-related barriers for adolescents with inflammatory bowel disease (IBD) and examine their relationship to 6-MP/azathioprine and 5-ASA medication adherence. METHODS:Participants included 74 adolescents, aged 13-17 years, diagnosed with IBD and their caregivers. Adolescents and caregivers jointly completed a measure of barriers to medication adherence. Adherence to medication was measured by family-report, pill-count, and serum assay. RESULTS: Families endorsed one to seven total barriers to medication adherence. The most commonly reported barriers included forgetting, being away from home, and interference with an activity. Neither demographic nor disease severity variables were related to the total number of reported barriers. Fewer total reported barriers was related to better adherence by adolescent and maternal report. CONCLUSION: Most families experience at least one barrier to treatment adherence. Effective problem-solving around these barriers and its integration into future treatment protocols may help improve medication adherence in the pediatric IBD population.
Authors: J S Hyams; G D Ferry; F S Mandel; J D Gryboski; P M Kibort; B S Kirschner; A M Griffiths; A J Katz; R J Grand; J T Boyle Journal: J Pediatr Gastroenterol Nutr Date: 1991-05 Impact factor: 2.839
Authors: S Lichtiger; D H Present; A Kornbluth; I Gelernt; J Bauer; G Galler; F Michelassi; S Hanauer Journal: N Engl J Med Date: 1994-06-30 Impact factor: 91.245
Authors: Kevin A Hommel; Julia Carmody; Andrew D Hershey; Christina Holbein; Marielle Kabbouche-Samaha; James Peugh; Scott Powers Journal: Headache Date: 2020-04-22 Impact factor: 5.887
Authors: Kevin A Hommel; Wendy N Gray; Elizabeth Hente; Katherine Loreaux; Richard F Ittenbach; Michele Maddux; Robert Baldassano; Francisco Sylvester; Wallace Crandall; Charles Doarn; Melvin B Heyman; David Keljo; Lee A Denson Journal: Contemp Clin Trials Date: 2015-05-21 Impact factor: 2.226
Authors: E M Venditti; K Tan; N Chang; L Laffel; G McGinley; N Miranda; J B Tryggestad; N Walders-Abramson; P Yasuda; L Delahanty Journal: Diabetes Res Clin Pract Date: 2018-02-08 Impact factor: 5.602
Authors: Jamie L Ryan; Michael W Mellon; Katherine W F Junger; Elizabeth A Hente; Lee A Denson; Shehzad A Saeed; Kevin A Hommel Journal: Inflamm Bowel Dis Date: 2013-11 Impact factor: 5.325